Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1986 Nov;45(11):941–944. doi: 10.1136/ard.45.11.941

Effect of treatment on erythrocyte phosphoribosyl pyrophosphate synthetase and glutathione reductase activity in patients with primary gout.

J Braven, T R Hardwell, P Hickling, M Whittaker
PMCID: PMC1002024  PMID: 3024593

Abstract

The activities of erythrocyte phosphoribosyl pyrophosphate (PRPP) synthetase and glutathione reductase (GTR) were studied in 26 patients with primary gout who were receiving no treatment or treatment with either allopurinol or azapropazone, and compared with the activity in a group of healthy controls. The activity of PRPP synthetase was significantly higher in the gout group and was not influenced by either drug. No significant difference in the activity of GTR was observed. The failure of either drug to suppress the increased activity of PRPP synthetase associated with gout is discussed.

Full text

PDF
941

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker M. A., Meyer L. J., Wood A. W., Seegmiller J. E. Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity. Science. 1973 Mar 16;179(4078):1123–1126. doi: 10.1126/science.179.4078.1123. [DOI] [PubMed] [Google Scholar]
  2. Bluestone R., Lewis B., Mervart I. Hyperlipoproteinaemia in gout. Ann Rheum Dis. 1971 Mar;30(2):134–137. doi: 10.1136/ard.30.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Braven J., Hardwell T. R., Seddon R., Whittaker M. A spectrophotometric assay of phosphoribosyl pyrophosphate synthetase. Ann Clin Biochem. 1984 Sep;21(Pt 5):366–371. doi: 10.1177/000456328402100505. [DOI] [PubMed] [Google Scholar]
  4. Ferns G. A., Lanham J., Stocks J., Ritchie C., Katz J., Galton D. J. The measurement of high density lipoprotein subfractions in patients with primary gout using a simple precipitation method. Ann Clin Biochem. 1985 Sep;22(Pt 5):526–532. doi: 10.1177/000456328502200511. [DOI] [PubMed] [Google Scholar]
  5. Fox I. H., Kelley W. N. Human phosphoribosylpyrophosphate synthetase. Distribution, purification, and properties. J Biol Chem. 1971 Sep 25;246(18):5739–5748. [PubMed] [Google Scholar]
  6. Gibson T., Grahame R. Gout and hyperlipidaemia. Ann Rheum Dis. 1974 Jul;33(4):298–303. doi: 10.1136/ard.33.4.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hardwell T. R., Braven J., Shaw S., Whittaker M. Phosphoribosyl pyrophosphate synthetase and glutathione reductase in erythrocytes from hyperuricaemic and gout patients. Clin Chim Acta. 1982 Dec 23;126(3):217–226. doi: 10.1016/0009-8981(82)90295-9. [DOI] [PubMed] [Google Scholar]
  8. Kum-Tatt L., Tan I. K., Seet A. M. A new colorimetric method for the determination of NADH/NADPH dependent glutathione reductase in erythrocytes and in plasma. Clin Chim Acta. 1975 Jan 20;58(2):101–108. doi: 10.1016/s0009-8981(75)80002-7. [DOI] [PubMed] [Google Scholar]
  9. Long W. K. Glutathione reductase in red blood cells: variant associated with gout. Science. 1967 Feb 10;155(3763):712–713. doi: 10.1126/science.155.3763.712. [DOI] [PubMed] [Google Scholar]
  10. Naito H. K., Mackenzie A. H. Secondary hypertriglyceridemia and hyperlipoproteinemia in patients with primary asymptomatic gout. Clin Chem. 1979 Mar;25(3):371–375. [PubMed] [Google Scholar]
  11. Nishida Y., Akaoka I., Nishizawa T., Yoshimura T. Hyperlipidaemia in gout. Clin Chim Acta. 1975 Jul 9;62(1):103–106. doi: 10.1016/0009-8981(75)90285-5. [DOI] [PubMed] [Google Scholar]
  12. Salkie M. L., Simpson E. The erythrocyte glutathione reductase activity (E.C. 1.6.4.2) of healthy blood donors. J Clin Pathol. 1970 Nov;23(8):708–710. doi: 10.1136/jcp.23.8.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sperling O., Boer P., Persky-Brosh S., Kanarek E., De Vries A. Altered kinetic property of erythrocyte phosphoribosylpsyrophosphate synthetase in excessive purine production. Rev Eur Etud Clin Biol. 1972 Aug-Sep;17(7):703–706. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES